Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough

TLDR

• Moderna shares surged 16% to $50 on Wednesday following positive five-year melanoma vaccine trial data
• Combined treatment with Merck’s Keytruda showed 49% reduction in cancer recurrence or death risk
• Company is diversifying beyond COVID vaccines into cancer treatments and respiratory vaccines
• Analysts maintain Hold rating with $29.93 average price target, implying 39.91% downside
• Additional trials underway for lung, kidney, and bladder cancer applications

---

Moderna shares jumped approximately 16% during Wednesday’s session. The stock reached $50, establishing a new 52-week high.

Moderna, Inc., MRNA

The rally came after Moderna and Merck released five-year trial data for their melanoma vaccine. The results showed strong patient outcomes over an extended period.

Patients with high-risk melanoma who received the combination therapy saw major benefits. The treatment reduced recurrence or death risk by 49% compared to Keytruda alone.

The experimental vaccine is called intismeran autogene. It uses mRNA technology to create personalized treatments based on individual tumor mutations.

Dr. Marjorie Green from Merck called the longer-term data a meaningful milestone. She noted that stage III/IV melanoma patients face high recurrence risk after surgery.

Expanding Beyond COVID Vaccines

Moderna is transforming its business model. The company is moving from a single-product COVID vaccine business to a diversified biotech.

The melanoma vaccine partnership with Merck represents the biggest growth opportunity. Investors are watching for Phase 3 trial progress and expansion into additional cancer types.

Moderna is also developing a respiratory vaccine portfolio. Flu, RSV, and combination shots could generate recurring annual revenue streams.

Cost-cutting measures and manufacturing improvements are underway. These efforts are pushing the company closer to profitability.

Government contracts and global distribution agreements provide additional revenue stability. Cancer vaccine partnerships strengthen the overall business foundation.

Multiple Cancer Types Under Investigation

The personalized vaccine technology is being tested across several cancer types. Moderna and Merck are running trials for lung cancer patients.

Kidney cancer studies are also in progress. Bladder cancer represents another area of active research.

Dr. Kyle Holen from Moderna emphasized the company’s oncology investment strategy. He stated the encouraging outcomes illustrate mRNA’s potential in cancer care.

The therapy works by triggering an antitumor immune response. Each treatment is customized to match mutations in a patient’s specific tumor.

Wall Street Remains Cautious

Despite Wednesday’s rally, analyst sentiment stays neutral. The consensus rating is Hold based on one Buy, 15 Hold, and four Sell recommendations.

The average price target stands at $29.93. This represents 39.91% downside from current levels.

Moderna faces tough competition in the vaccine space. Pfizer, BioNTech, GSK, and Sanofi are all investing heavily in respiratory and cancer vaccines.

Revenue is not expected to reach pandemic-era levels anytime soon. The company peaked during the COVID vaccine rollout years.

The five-year melanoma data provides evidence of treatment durability. Patients who underwent surgery for high-risk melanoma showed sustained benefits from the combination therapy approach.

The post Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough appeared first on Blockonomi.